-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s AAV-GAD
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's AAV-GAD report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: MeiraGTx Holdings Plc’s AAV-AQP1
Empower your strategies with our Net Present Value Model: MeiraGTx Holdings Plc's AAV-AQP1 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAV-AQP1 in Xerostomia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAV-AQP1 in Xerostomia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAV-AQP1 in Xerostomia Drug Details: AAV-AQP1 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-710 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-710 in Cystic Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-710 in Cystic Fibrosis Drug Details: 4D-710 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VYTAU-01 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VYTAU-01 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VYTAU-01 in Alzheimer's Disease Drug Details: VYTAU-01 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JWK-006 in Juvenile Macular Degeneration (Stargardt Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JWK-006 in Juvenile Macular Degeneration (Stargardt Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JWK-006 in Juvenile Macular Degeneration (Stargardt Disease) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XM-001 in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XM-001 in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XM-001 in Wet (Neovascular / Exudative) Macular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dirloctocogene Samoparvovec in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dirloctocogene Samoparvovec in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dirloctocogene Samoparvovec in Hemophilia A (Factor VIII...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-1005 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-1005 in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-1005 in Parkinson's Disease Drug Details: Gene therapy is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TSHA-102 in Rett Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TSHA-102 in Rett Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TSHA-102 in Rett Syndrome Drug Details: TSHA-102 (TGTX-104) is under development...